Roivant Sciences Ltd.
ROIV
$36.36
$0.060.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.53M | 8.26M | 13.31M | 20.33M | 23.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.53M | 8.26M | 13.31M | 20.33M | 23.23M |
| Cost of Revenue | 731.82M | 682.60M | 628.38M | 602.45M | 579.68M |
| Gross Profit | -724.29M | -674.34M | -615.07M | -582.12M | -556.44M |
| SG&A Expenses | 643.17M | 609.56M | 664.18M | 621.47M | 688.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.37B | 1.29B | 1.29B | 1.22B | 1.27B |
| Operating Income | -1.37B | -1.28B | -1.28B | -1.20B | -1.24B |
| Income Before Tax | -289.88M | -264.58M | -921.73M | -865.87M | -931.21M |
| Income Tax Expenses | 124.72M | 133.33M | 84.30M | 35.40M | 40.86M |
| Earnings from Continuing Operations | -414.60 | -397.91 | -1.01K | -901.27 | -972.07 |
| Earnings from Discontinued Operations | -- | -- | 0.00 | 327.02M | 283.94M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 148.35M | 98.14M | 196.79M | 200.28M | 197.50M |
| Net Income | -266.25M | -299.77M | -809.24M | -373.97M | -490.63M |
| EBIT | -1.37B | -1.28B | -1.28B | -1.20B | -1.24B |
| EBITDA | -1.36B | -1.28B | -1.27B | -1.19B | -1.23B |
| EPS Basic | -0.38 | -0.45 | -1.17 | -0.55 | -0.70 |
| Normalized Basic EPS | -0.89 | -0.90 | -0.74 | -0.63 | -0.61 |
| EPS Diluted | -0.54 | -0.60 | -1.17 | -0.56 | -0.70 |
| Normalized Diluted EPS | -0.84 | -0.85 | -0.74 | -0.63 | -0.61 |
| Average Basic Shares Outstanding | 2.80B | 2.76B | 2.77B | 2.79B | 2.85B |
| Average Diluted Shares Outstanding | 2.91B | 2.87B | 2.77B | 2.79B | 2.85B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |